Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dupilumab · Dupixent, SAR-231893

Monoclonal antibody · Antagonist of Interleukin-4 receptor alpha subunit (IL4R) · developed by Regeneron Pharmaceuticals

Approved FDA, Mar 2017
REGN Developer
3 Registered trials

What is Dupilumab?

Dupilumab is a human IgG4 monoclonal antibody that binds the IL-4 receptor alpha subunit, blocking signaling by both IL-4 and IL-13. It is studied in atopic dermatitis and asthma, and is used in several other type 2 inflammatory conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Dupixent, SAR-231893, REGN-668
Drug type
Monoclonal antibody
Targets
Interleukin-4 receptor alpha subunit (IL4R)
Mechanism
Antagonist of Interleukin-4 receptor alpha subunit (IL4R)
Pathways
IL-4 and IL-13 signaling, type I and type II receptor signaling, IgE release and proinflammatory cytokine release
Therapy area
Dermatology, Immunology, Respiratory
Developer
Regeneron Pharmaceuticals (REGN)
Also in trials of
SNY
FDA status
Approved as Dupixent (March 28, 2017), BLA761055 · FDA label
UNII
420K487FSG

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05268107 Phase 4 Atopic Dermatitis Recruiting REGN
NCT07919899 Phase 3 Dermatitis Atopic Not yet recruiting SNY
NCT07309614 Phase 3 Asthma Control Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Asthma ControlAtopic DermatitisDermatitis Atopic

Other drugs acting on IL4R

More from Regeneron Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Dupilumab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.